March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
3 citations
,
January 2025 in “Journal of Natural Products” Calancardin B may help reduce inflammation in immune cells.
5 citations
,
May 2023 in “Clinical Rheumatology” Tofacitinib helped regrow hair in a lupus patient with alopecia.
111 citations
,
June 2015 in “Age and Ageing” Dutasteride, fesoterodine, and finasteride are beneficial for older patients, while most other drugs should be used cautiously or avoided.
19 citations
,
April 2019 in “Veterinary dermatology” Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.
May 2024 in “Drugs & Therapy Perspectives” New treatments like JAK inhibitors offer hope for better alopecia areata management.
10 citations
,
January 2014 in “Journal of Pharmaceutical Sciences” Balancing lipophilicity and solubility is key for effective and safe ketorolac prodrugs.
June 2025 in “British Journal of Dermatology” Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.
14 citations
,
October 1977 in “The Lancet”
2 citations
,
November 2018 in “Indian Journal of Pharmaceutical Education” The developed model can predict effective 5-alpha-reductase enzyme inhibitors.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
September 2022 in “Journal of The American Academy of Dermatology” Dermatologists should monitor potassium levels in women taking spironolactone for acne, hair loss, and hirsutism.
105 citations
,
October 2018 in “Nature” A small group of slow-growing cells causes basal cell carcinoma to return after treatment.
37 citations
,
August 2022 in “Frontiers in pharmacology” Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
52 citations
,
July 1998 in “Urology” Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
22 citations
,
January 2001 in “Chemical & Pharmaceutical Bulletin” Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.
75 citations
,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
October 2025 in “International Journal of Dermatology” JAK inhibitors may help treat certain types of hair loss, but more research is needed.
20 citations
,
June 1995 in “Tetrahedron Letters” New chemicals were made that can block an enzyme linked to hair loss, prostate growth, and acne.
14 citations
,
February 1998 in “Bioorganic & Medicinal Chemistry Letters” Some newly made compounds can block an enzyme linked to hair loss and prostate growth, with one in particular being very selective.
1 citations
,
March 2004 in “Journal of the American Academy of Dermatology” ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
196 citations
,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
January 2006 in “Atherosclerosis Supplements” 53 citations
,
July 2018 in “Drug design, development and therapy” Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
6 citations
,
May 2013 in “Journal of Clinical Oncology” Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
505 citations
,
October 2011 in “Journal of clinical oncology” MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.
November 2025 in “Journal of Investigative Dermatology”
August 2025 in “Journal of Investigative Dermatology” Elevated luteinizing hormone contributes to female-pattern hair loss, and blocking certain channels may help prevent it.
1 citations
,
July 1990 in “European Journal of Pharmacology”
May 2022 in “Gastroenterology” Targeting NETs may help reduce fibrosis in Crohn's disease.